64Cu-SAR-bisPSMA not checked

Clarity Pharmaceuticals Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.”In the company’s words, NCT06056830 on ClinicalTrials.gov
Tested for
Prostate Cancer (2 trials), Prostatic Neoplasms, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated by Radiotherapy, Cryotherapy, Prostatic Neoplasms, Castration-Resistant
Main trialPhase 3
“The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.”In the company’s words, NCT06056830 on ClinicalTrials.gov

Other drugs for Prostate Cancer

All 195 drugs for Prostate Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Sep 2026 Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Phase 3Active, not recruiting 31 Dec 2026 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Phase 1/2Recruiting Sep 2026 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Phase 1/2Completed 8 Aug 2023 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
Phase 1Completed 19 Oct 2022 Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow 64Cu-SAR-bisPSMA

Following is part of Solo: you see every change to 64Cu-SAR-bisPSMA the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in